Journal
APPLIED HEALTH ECONOMICS AND HEALTH POLICY
Volume 19, Issue 5, Pages 735-745Publisher
SPRINGER INT PUBL AG
DOI: 10.1007/s40258-021-00673-1
Keywords
-
Funding
- Celltrion Healthcare
Ask authors/readers for more resources
The introduction of CT-P13 SC may lead to substantial cost savings for the UK society.
Background CT-P13 subcutaneous (SC)-the first and only SC version of infliximab-is approved by the European Medicines Agency for the treatment of rheumatoid arthritis (RA). This new mode of infliximab administration will allow patients to self-inject at home, significantly reducing the number of outpatient visits and costs of intravenous (IV) administration. This paper describes the economic impact of introducing CT-P13 SC to the market from the UK societal perspective. Objective The budget impact analysis was conducted to assess the financial impact of the adoption of CT-P13 SC over a 5-year period. Methods A prevalence-based budget impact model was developed incorporating epidemiological data, administration cost data, and market share data. The analysis compared a world with CT-P13 SC scenario to a world without CT-P13 SC. A sensitivity analysis included dose escalation up to 4.1 mg/kg to reflect the real-world care delivery setting. Results Compared to the world without scenario, the introduction of CT-P13 SC resulted in cost savings of 69.3 pound million in the UK over a 5-year period. In the scenario analysis, the saving increased to 173.5 pound million over 5 years. Conclusion Use of CT-P13 SC may lead to substantial cost savings for the UK society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available